Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report

Case Rep Oncol. 2023 Feb 17;16(1):75-81. doi: 10.1159/000529447. eCollection 2023 Jan-Dec.

Abstract

Primary pleural angiosarcoma (PPA) is a rare and clinically fatal pleural tumor originating from vascular endothelial cells. Herein, we presented the case of a 73-year-old man who was referred to our emergency room with complaints of right chest and back pain for a few days. Chest computed tomography revealed massive pleural effusion and a large mass in the right chest cavity. Thoracoscopic examination demonstrated a large hemorrhagic tumor on the parietal pleura whose pathological analysis indicated PPA. The patient received immunotherapy combined with nivolumab and ipilimumab. A cycle of nivolumab and ipilimumab improved his hemorrhagic anemia and reduced the pleural effusion and tumor size. This treatment outcome suggests that nivolumab and ipilimumab comprise a vital treatment option for PPA.

Keywords: Case report; Ipilimumab; Nivolumab; Primary pleural angiosarcoma.

Publication types

  • Case Reports

Grants and funding

No funding was received.